ScreenerHero

RIGL Rigel Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · rigel.com
47.99USD+4.08%Mkt Cap: 887.91M $P/E: 2.84

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap887.91M USD
Enterprise Value805.95M USD
Revenue (TTM)276.78M USD
Gross Profit274.66M USD
Net Income (TTM)367.02M USD
Revenue/Share15.12 USD
Last Price47.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees172
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.84
P/E (Forward)9.34
PEG—
EV/EBITDA8.98
EV/Revenue2.91
P/S3.08
P/B2.02
EPS (TTM)16.25
EPS (Forward)4.94
52W Range
24.9584% of range52.24
52W High52.24 USD
52W Low24.95 USD
Profitability
Gross Margin93.33%
Oper. Margin29.95%
EBITDA Margin32.41%
Profit Margin124.72%
ROE93.75%
ROA71.46%
Growth
Revenue Growth-22.60%
Earnings Growth-73.20%
Cash Flow & Leverage
Operating CF75.66M USD
CapEx (TTM)—
FCF Margin-11.47%
FCF Yield-3.58%
Net Debt-55.38M USD
Net Debt/EBITDA-0.62
Balance Sheet
Debt/Equity0.14
Current Ratio1.94
Quick Ratio1.58
Book Value/Sh22.81 USD
Cash/Share5.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 27, 2024
Analyst Consensus
Rating—
Target (Mean)63.00 USD
Upside (mean)+31.3%
Target Range43.00 USD – 85.00 USD
43.00+31.3% to mean85.00
# Analysts5
Ownership
Shares Out.18.50M
Float14.84M
Insiders3.35%
Institutions89.27%
Short Interest
Short Ratio11.3d
Short % Float17.54%
Short % Out.17.09%
Shares Short3.19M
Short (prev mo.)3.20M
Technical
SMA 5044.88 (+6.9%)
SMA 20036.59 (+31.2%)
Beta1.19
S&P 52W Chg16.45%
Avg Vol (30d)247.95K
Avg Vol (10d)213.03K
Technical Indicators
RSI (14)55.7
MACD0.8859
MACD Signal1.2298
MACD Hist.-0.3439
BB Upper49.88 USD
BB Middle47.48 USD
BB Lower45.09 USD
BB Width10.09%
ATR (14)1.888 USD
Vol Ratio (20d)0.96x